Keyphrases
Cardiovascular Risk
100%
Practical Guidance
100%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
100%
Clinical Trials
50%
Monoclonal Antibody
25%
Low-density Lipoprotein Cholesterol (LDL-C)
25%
Cardiovascular Outcomes
25%
Cost-effectiveness
25%
Current Guidelines
25%
Guideline Recommendations
25%
Atherosclerotic Cardiovascular Disease (ASCVD)
25%
Commercial Use
25%
Significant Experiences
25%
Antibody Class
25%
Medicine and Dentistry
Cardiovascular Risk
100%
Proprotein Convertase 9
100%
Clinical Trial
50%
Cardiovascular System
25%
Monoclonal Antibody
25%
Low Density Lipoprotein Cholesterol
25%
Cost-Effectiveness Analysis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
Proprotein Convertase 9
100%
Clinical Trial
50%
Coronary Artery Atherosclerosis
25%
Monoclonal Antibody
25%
Low Density Lipoprotein Cholesterol
25%